



ELSEVIER

Clinica Chimica Acta 260 (1997) 217–218



Author index

Volume 260 (1997)

- Alberti, M.M., see Dyer, R.G. 260, 1
- Author, D., The effect of analytic uncertainty on clinical decision making 260, 97
- Barragán-González, E., J.A. López-Guerrero, P. Bolufer-Gilabert, M. Sanz-Alonso, J. De la Rubia-Comos, A. Sempere-Talens, The type of reverse transcriptase affects the sensitivity of some reverse transcription PCR methods 260, 73
- Bertuzzi, A., see Mingrone, G. 260, 27
- Biondi, R., see Capodicasa, E. 260, 35
- Blaabjerg, O., see Hyltoft Petersen, P. 260, 189
- Bolufier-Gilabert, P., see Barragán-González, E. 260, 73
- Büttner, J., Diagnostic validity as a theoretical concept and as a measurable quantity 260, 131
- Capodicasa, E., C. Tassi, R. Rossi, L. Mezzasoma, M. Valiani, R. Biondi, Effect of antiorthostatic hypokinetic/hypodynamia on urinary endothelin-1 and *N*-acetyl- β -D-glucosaminidase excretion in rats 260, 35
- Chiang, A.N., B. Hwang, G.C. Shaw, B.C. Lee, J.H. Lu, C.C.L. Meng, P. Chou, Changes in plasma levels of lipids and lipoprotein composition in patients with Kawasaki disease 260, 15
- Chou, P., see Chiang, A.N. 260, 15
- Davie, S.J., see Gould, B.J. 260, 49
- De la Rubia-Comos, J., see Barragán-González, E. 260, 73
- De Smet, R., see Mingrone, G. 260, 27
- de Verdier, C.-H., see Hyltoft Petersen, P. 260, 189
- Doumas, B.T., The evolution and limitations of accuracy and precision standards 260, 145
- Dyer, R.G., M.W. Stewart, J. Mitcheson, K. George, M.M. Alberti, M.F. Laker, 7-Ketocholesterol, a specific indicator of lipoprotein oxidation, and malondialdehyde in non-insulin dependent diabetes and peripheral vascular disease 260, 1
- Fraser, C.G., see Hyltoft Petersen, P. 260, 189
- Gandolfi, A., see Mingrone, G. 260, 27
- George, K., see Dyer, R.G. 260, 1
- Gould, B.J., S.J. Davie, J.S. Yudkin, Investigation of the mechanism underlying the variability of glycated haemoglobin in non-diabetic subjects not related to glycaemia 260, 49
- Greco, A.V., see Mingrone, G. 260, 27
- Groth, T., see Hyltoft Petersen, P. 260, 189
- Handorf, C.R., Assuring quality in laboratory testing at the point of care 260, 207
- Howanitz, P.J., G.A. Tetrault, S.J. Steindel, Clinical laboratory quality control: a costly process now out of control 260, 163
- Hørder, M., see Hyltoft Petersen, P. 260, 189
- Hwang, B., see Chiang, A.N. 260, 15
- Hyltoft Petersen, P., C.-H. de Verdier, T. Groth, C.G. Fraser, O. Blaabjerg, M. Hørder, The influence of analytical bias on diagnostic misclassifications 260, 189
- Klee, G., A conceptual model for establishing tolerance limits for analytic bias and imprecision based on variations in population test distributions 260, 175

- Laker, M.F., see Dyer, R.G. 260, 1
- Lascelles, C.V., P.A. Quant, Investigation of human hepatic mitochondrial 3-hydroxy-3-methylglutaryl-coenzyme A synthase in post-mortem or biopsy tissue 260, 85
- Lee, B.C., see Chiang, A.N. 260, 15
- López-Guerrero, J.A., see Barragán-González, E. 260, 73
- Lu, J.H., see Chiang, A.N. 260, 15
- Meng, C.C.L., see Chiang, A.N. 260, 15
- Mezzasoma, L., see Capodicasa, E. 260, 35
- Mingrone, G., R. De Smet, A.V. Greco, A. Bertuzzi, A. Gandolfi, S. Ringoir, R. Vanholder, Serum uremic toxins from patients with chronic renal failure displace the binding of L-tryptophan to human serum albumin 260, 27
- Mitcheson, J., see Dyer, R.G. 260, 1
- Quant, P.A., see Lascelles, C.V. 260, 85
- Ringoir, S., see Mingrone, G. 260, 27
- Rojas, G., see Sorell Gómez, L. 260, 65
- Rossi, R., see Capodicasa, E. 260, 35
- Sanz-Alonso, M., see Barragán-González, E. 260, 73
- Sempere-Talens, A., see Barragán-González, E. 260, 73
- Shaw, G.C., see Chiang, A.N. 260, 15
- Sorell Gómez, L., G. Rojas, A simple visual immunoassay (VIA) for rapid identification of high lipoprotein(a) blood levels 260, 65
- Steindel, S.J., see Howanitz, P.J. 260, 163
- Stewart, M.W., see Dyer, R.G. 260, 1
- Tassi, C., see Capodicasa, E. 260, 35
- Tetrault, G.A., see Howanitz, P.J. 260, 163
- Valiani, M., see Capodicasa, E. 260, 35
- Vanholder, R., see Mingrone, G. 260, 27
- Werner, M., Linking analytic performance goals to medical outcome 260, 99
- Witte, D.L., The complex connections between test properties and relevant outcomes: widening the perspective 260, 117
- Yudkin, J.S., see Gould, B.J. 260, 49

Subject index

Volume 260 (1997)

- Albumin binding;** Uremic toxins; Chronic renal failure; L-Tryptophan **260, 27**
- Aminoglycosides;** Predictive value; Cognition; Hemochromatosis; Error rates; Analytical goals **260, 117**
- Analytical goals;** Analytical quality specifications; Glycated haemoglobin; S-Cholesterol; S-Transferrin **260, 189**
- Analytical goals;** Predictive value; Cognition; Hemochromatosis; Aminoglycosides; Error rates **260, 117**
- Analytical quality specifications;** Analytical goals; Glycated haemoglobin; S-Cholesterol; S-Transferrin **260, 189**
- Analytic bias;** Analytic goals; Imprecisions; Clinical decision theory; Quality control; Tolerance limits **260, 175**
- Analytic goals;** Analytic bias; Imprecisions; Clinical decision theory; Quality control; Tolerance limits **260, 175**
- Analytic performance;** Medical goals; Tolerance limits; Clinical decisions; Medical reasoning **260, 99**
- Antiorthostasis;** Endothelin-1 (ET-1); *N*-acetyl- β -D-glucosaminidase (NAG); Kidney; Urine; Rat **260, 35**
- Apolipoproteins;** Lipids; Lipoproteins; Kawasaki disease **260, 15**
- Atherosclerosis;** Diabetes; Malondialdehyde; Lipoproteins; 7-Ketocholesterol **260, 1**
- Avian Myelomatosis Virus (AMV);** Reverse transcription (RT); Murine Moloney Leukaemia Virus (MMLV); RT-PCR; PML/RAR α ; CBF β /MYH11; Cytokeratin K19 **260, 73**
- CBF β /MYH11;** Reverse transcription (RT); Avian Myelomatosis Virus (AMV); Murine Moloney Leukaemia Virus (MMLV); RT-PCR; PML/RAR α ; Cytokeratin K19 **260, 73**
- Chronic renal failure;** Uremic toxins; L-Tryptophan; Albumin binding **260, 27**
- Clinical assay;** Human hepatic mHMG-CoA synthase; Succinylation; Ketogenesis; Liver needle biopsy; Postmortem tissue **260, 85**
- Clinical decisions;** Analytic performance; Medical goals; Tolerance limits; Medical reasoning **260, 99**
- Clinical decision theory;** Analytic goals; Analytic bias; Imprecisions; Quality control; Tolerance limits **260, 175**
- Cognition;** Predictive value; Hemochromatosis; Aminoglycosides; Error rates; Analytical goals **260, 117**
- Cytokeratin K19;** Reverse transcription (RT); Avian Myelomatosis Virus (AMV); Murine Moloney Leukaemia Virus (MMLV); RT-PCR; PML/RAR α ; CBF β /MYH11 **260, 73**

- Diabetes;** Atherosclerosis; Malondialdehyde; Lipoproteins; 7-Ketocholesterol **260, 1**
- Diagnostic validity;** Laboratory test; Laboratory finding; Efficiency **260, 131**
- 2,3-Diphosphoglycerate;** Glycated haemoglobin; Glycated albumin; Fructosamine; Glucose tolerance test; Glucose permeability of erythrocytes **260, 49**
- Efficiency;** Laboratory test; Laboratory finding; Diagnostic validity **260, 131**
- Endothelin-1 (ET-1);** Antiorthostasis; *N*-acetyl- β -D-glucosaminidase (NAG); Kidney; Urine; Rat **260, 35**
- Error rates;** Predictive value; Cognition; Hemochromatosis; Aminoglycosides; Analytical goals **260, 117**
- Fructosamine;** Glycated haemoglobin; Glycated albumin; Glucose tolerance test; Glucose permeability of erythrocytes; 2,3-Diphosphoglycerate **260, 49**
- Glucose permeability of erythrocytes;** Glycated haemoglobin; Glycated albumin; Fructosamine; Glucose tolerance test; 2,3-Diphosphoglycerate **260, 49**
- Glucose tolerance test;** Glycated haemoglobin; Glycated albumin; Fructosamine; Glucose permeability of erythrocytes; 2,3-Diphosphoglycerate **260, 49**
- Glycated albumin;** Glycated haemoglobin; Fructosamine; Glucose tolerance test; Glucose permeability of erythrocytes; 2,3-Diphosphoglycerate **260, 49**
- Glycated haemoglobin;** Analytical goals; Analytical quality specifications; S-Cholesterol; S-Transferrin **260, 189**
- Glycated haemoglobin;** Glycated albumin; Fructosamine; Glucose tolerance test; Glucose permeability of erythrocytes; 2,3-Diphosphoglycerate **260, 49**
- Hemochromatosis;** Predictive value; Cognition; Aminoglycosides; Error rates; Analytical goals **260, 117**
- Human hepatic mHMG-CoA synthase;** Succinylation; Ketogenesis; Clinical assay; Liver needle biopsy; Postmortem tissue **260, 85**
- Imprecisions;** Analytic goals; Analytic bias; Clinical decision theory; Quality control; Tolerance limits **260, 175**
- Kawasaki disease;** Lipids; Lipoproteins; Apolipoproteins **260, 15**
- 7-Ketocholesterol;** Atherosclerosis; Diabetes; Malondialdehyde; Lipoproteins **260, 1**
- Ketogenesis;** Human hepatic mHMG-CoA synthase; Succinylation; Clinical assay; Liver needle biopsy; Postmortem tissue **260, 85**
- Kidney;** Antiorthostasis; Endothelin-1 (ET-1); *N*-acetyl- β -D-glucosaminidase (NAG); Urine; Rat **260, 35**
- Laboratory costs;** Quality control; Timeliness; Quality costs; Quality improvement; Laboratory management **260, 163**
- Laboratory finding;** Laboratory test; Diagnostic validity; Efficiency **260, 131**
- Laboratory management;** Quality control; Laboratory costs; Timeliness; Quality costs; Quality improvement **260, 163**
- Laboratory testing;** Point of care; Quality **260, 207**
- Laboratory test;** Laboratory finding; Diagnostic validity; Efficiency **260, 131**
- Lipids;** Lipoproteins; Apolipoproteins; Kawasaki disease **260, 15**
- Lipoprotein(a);** Visual immunoassay; Monoclonal antibodies **260, 65**
- Lipoproteins;** Atherosclerosis; Diabetes; Malondialdehyde; 7-Ketocholesterol **260, 1**
- Lipoproteins;** Lipids; Apolipoproteins; Kawasaki disease **260, 15**
- Liver needle biopsy;** Human hepatic mHMG-CoA synthase; Succinylation; Ketogenesis; Clinical assay; Postmortem tissue **260, 85**

- L-Tryptophan**; Uremic toxins; Chronic renal failure; Albumin binding **260**, 27
- Malondialdehyde**; Atherosclerosis; Diabetes; Lipoproteins; 7-Ketocholesterol **260**, 1
- Medical goals**; Analytic performance; Tolerance limits; Clinical decisions; Medical reasoning **260**, 99
- Medical reasoning**; Analytic performance; Medical goals; Tolerance limits; Clinical decisions **260**, 99
- Monoclonal antibodies**; Lipoprotein(a); Visual immunoassay **260**, 65
- Murine Moloney Leukaemia Virus (MMLV)**; Reverse transcription (RT); Avian Myelomatosis Virus (AMV); RT-PCR; PML/RAR α ; CBF β /MYH11; Cytokeratin K19 **260**, 73
- N-acetyl- β -D-glucosaminidase (NAG)**; Antiorthostasis; Endothelin-1 (ET-1); Kidney; Urine; Rat **260**, 35
- PML/RAR α** ; Reverse transcription (RT); Avian Myelomatosis Virus (AMV); Murine Moloney Leukaemia Virus (MMLV); RT-PCR; CBF β /MYH11; Cytokeratin K19 **260**, 73
- Point of care**; Laboratory testing; Quality **260**, 207
- Postmortem tissue**; Human hepatic mHMG-CoA synthase; Succinylation; Ketogenesis; Clinical assay; Liver needle biopsy **260**, 85
- Predictive value**; Cognition; Hemochromatosis; Aminoglycosides; Error rates; Analytical goals **260**, 117
- Quality control**; Analytic goals; Analytic bias; Imprecisions; Clinical decision theory; Tolerance limits **260**, 175
- Quality control**; Laboratory costs; Timeliness; Quality costs; Quality improvement; Laboratory management **260**, 163
- Quality costs**; Quality control; Laboratory costs; Timeliness; Quality improvement; Laboratory management **260**, 163
- Quality improvement**; Quality control; Laboratory costs; Timeliness; Quality costs; Laboratory management **260**, 163
- Quality**; Laboratory testing; Point of care **260**, 207
- Rat**; Antiorthostasis; Endothelin-1 (ET-1); N-acetyl- β -D-glucosaminidase (NAG); Kidney; Urine **260**, 35
- Reverse transcription (RT)**; Avian Myelomatosis Virus (AMV); Murine Moloney Leukaemia Virus (MMLV); RT-PCR; PML/RAR α ; CBF β /MYH11; Cytokeratin K19 **260**, 73
- RT-PCR**; Reverse transcription (RT); Avian Myelomatosis Virus (AMV); Murine Moloney Leukaemia Virus (MMLV); PML/RAR α ; CBF β /MYH11; Cytokeratin K19 **260**, 73
- S-Cholesterol**; Analytical goals; Analytical quality specifications; Glycated haemoglobin; S-Transferrin **260**, 189
- S-Transferrin**; Analytical goals; Analytical quality specifications; Glycated haemoglobin; S-Cholesterol **260**, 189
- Succinylation**; Human hepatic mHMG-CoA synthase; Ketogenesis; Clinical assay; Liver needle biopsy; Postmortem tissue **260**, 85
- Timeliness**; Quality control; Laboratory costs; Quality costs; Quality improvement; Laboratory management **260**, 163
- Tolerance limits**; Analytic goals; Analytic bias; Imprecisions; Clinical decision theory; Quality control **260**, 175
- Tolerance limits**; Analytic performance; Medical goals; Clinical decisions; Medical reasoning **260**, 99
- Uremic toxins**; Chronic renal failure; L-Tryptophan; Albumin binding **260**, 27
- Urine**; Antiorthostasis; Endothelin-1 (ET-1); N-acetyl- β -D-glucosaminidase (NAG); Kidney; Rat **260**, 35
- Visual immunoassay**; Lipoprotein(a); Monoclonal antibodies **260**, 65